Vandetanib Shows Clinical Benefit When Combined With Docetaxel For Lung Cancer
Tuesday, June 2, 2009 - 21:21
in Health & Medicine
When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research.